|
1
|
Picci P: Osteosarcoma (osteogenic
sarcoma). Orphanet J Rare Dis. Jan 27–2007.(Epub ahead of print).
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Meyers PA, Heller G, Healey J, Huvos A,
Lane J, Marcove R, Applewhite A, Vlamis V and Rosen G: Chemotherapy
for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering
experience. J Clin Oncol. 10:5–15. 1992.PubMed/NCBI
|
|
3
|
Harris MB, Gieser P, Goorin AM, Ayala A,
Shochat SJ, Ferguson WS, Holbrook T and Link MP: Treatment of
metastatic osteosarcoma at diagnosis: A Pediatric Oncology Group
Study. J Clin Oncol. 16:3641–3648. 1998.PubMed/NCBI
|
|
4
|
Bacci G, Ferrari S, Longhi A, Forni C,
Zavatta M, Versari M and Smith K: High-grade osteosarcoma of the
extremity: Differences between localized and metastatic tumors at
presentation. J Pediatr Hematol Oncol. 24:27–30. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Meyers PA, Heller G, Healey JH, Huvos A,
Applewhite A, Sun M and LaQuaglia M: Osteogenic sarcoma with
clinically detectable metastasis at initial presentation. J Clin
Oncol. 11:449–453. 1993.PubMed/NCBI
|
|
6
|
Pacquement H, Kahfa C, Fagnou C, Demaille
MC, Brunat-Mentigny M, Sariban E, Perel Y and Zucker JM: Metastatic
osteogenic sarcoma (OS) at diagnosis. Study of 73 cases from the
French Society of Pediatric Oncology (SFOP) between 1980 and 1990.
Eur J Cancer. 33:S1241997. View Article : Google Scholar
|
|
7
|
Marina NM, Pratt CB, Rao BN, Shema SJ and
Meyer WH: Improved prognosis of children with osteosarcoma
metastatic to the lung(s) at the time of diagnosis. Cancer.
70:2722–2727. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kaste SC, Pratt CB, Cain AM, Jones-Wallace
DJ and Rao BN: Metastases detected at the time of diagnosis of
primary pediatric extremity osteosarcoma at diagnosis: Imaging
features. Cancer. 86:1602–1608. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baum ES, Gaynon P, Greenberg L, Krivit W
and Hammond D: Phase II study of cis-dichlorodiammineplatinum (II)
in childhood osteosarcoma: Children's Cancer Study Group Report.
Cancer Treat Rep. 63:1621–1627. 1979.PubMed/NCBI
|
|
10
|
Cores EP, Holland JF, Wang JJ and Sinks
LF: Doxorubicin in disseminated osteosarcoma. JAMA. 221:1132–1138.
1972. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jaffe N, Paed D, Farber S, Traggis D,
Geiser C, Kim BS, Das L, Frauenberger G, Djerassi I and Cassady JR:
Favorable response of metastatic osteogenic sarcoma to pulse
high-dose methotrexate with citrovorum rescue and radiation
therapy. Cancer. 31:1367–1373. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marti C, Kroner T, Remagen W, Berchtold W,
Cserhati M and Varini M: High-dose ifosfamide in advanced
osteosarcoma. Cancer Treat Rep. 69:115–117. 1985.PubMed/NCBI
|
|
13
|
Nitschke R, Starling KA, Vats T and Bryan
H: Cis-diamminedichloroplatinum (NSC-119875) in childhood
malignancies: A Southwest Oncology Group study. Med Pediatr Oncol.
4:127–132. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hamakawa H, Nakashiro K, Sumida T,
Shintani S, Myers JN, Takes RP, Rinaldo A and Ferlito A: Basic
evidence of molecular targeted therapy for oral cancer and salivary
gland cancer. Head Neck. 30:800–809. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun J, Blaskovich MA, Knowles D, Qian Y,
Ohkanda J, Bailey RD, Hamilton AD and Sebti SM: Antitumor efficacy
of a novel class of non-thiol-containing peptidomimetic inhibitors
of farnesyltransferase and geranylgeranyltransferase I: Combination
therapy with the cytotoxic agents cisplatin, Taxol, and
gemcitabine. Cancer Res. 59:4919–4926. 1999.PubMed/NCBI
|
|
16
|
Sun L, Liang C, Shirazian S, Zhou Y,
Miller T, Cui J, Fukuda JY, Chu JY, Nematalla A, Wang X, et al:
Discovery of
5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic
acid (2-diethylaminoethyl) amide, a novel tyrosine kinase inhibitor
targeting vascular endothelial and platelet-derived growth factor
receptor tyrosine kinase. J Med Chem. 46:1116–1119. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bowman T, Yu H, Sebti S, Dalton W and Jove
R: Signal transducers and activators of transcription: Novel
targets for anticancer therapeutics. Cancer Control. 6:427–435.
1999.
|
|
18
|
Turkson J and Jove R: STAT proteins: Novel
molecular targets for cancer drug discovery. Oncogene.
19:6613–6626. 2000. View Article : Google Scholar
|
|
19
|
Bowman T, Garcia R, Turkson J and Jove R:
STATs in oncogenesis. Oncogene. 19:2474–2488. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shoemaker RH: The NCI60 human tumour cell
line anticancer drug screen. Nat Rev Cancer. 6:813–823. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jayaprakasam B, Seeram NP and Nair MG:
Anticancer and antiinflammatory activities of cucurbitacins from
Cucurbita andreana. Cancer Lett. 189:11–16. 2003. View Article : Google Scholar
|
|
22
|
Duncan KLK, Duncan MD, Alley MC and
Sausville EA: Cucurbitacin E-induced disruption of the actin and
vimentin cytoskeleton in prostate carcinoma cells. Biochem
Pharmacol. 52:1553–1560. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sun J, Blaskovich MA, Jove R, Livingston
SK, Coppola D and Sebti SM: Cucurbitacin Q: A selective STAT3
activation inhibitor with potent antitumor activity. Oncogene.
24:3236–3245. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rivat C, Rodrigues S, Bruyneel E, Piétu G,
Robert A, Redeuilh G, Bracke M, Gespach C and Attoub S: Implication
of STAT3 signaling in human colonic cancer cells during intestinal
trefoil factor 3 (TFF3) - and vascular endothelial growth
factor-mediated cellular invasion and tumor growth. Cancer Res.
65:195–202. 2005.PubMed/NCBI
|
|
25
|
Blaskovich MA, Sun J, Cantor A, Turkson J,
Jove R and Sebti SM: Discovery of JSI-124 (cucurbitacin I), a
selective Janus kinase/signal transducer and activator of
transcription 3 signaling pathway inhibitor with potent antitumor
activity against human and murine cancer cells in mice. Cancer Res.
63:1270–1279. 2003.PubMed/NCBI
|
|
26
|
Iwanski GB, Lee DH, En-Gal S, Doan NB,
Castor B, Vogt M, Toh M, Bokemeyer C, Said JW, Thoennissen NH, et
al: Cucurbitacin B, a novel in vivo potentiator of gemcitabine with
low toxicity in the treatment of pancreatic cancer. Br J Pharmacol.
160:998–1007. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lui VWY, Yau DMS, Wong EYL, Ng YK, Lau
CPY, Ho Y, Chan JP, Hong B, Ho K, Cheung CS, et al: Cucurbitacin I
elicits anoikis sensitization, inhibits cellular invasion and in
vivo tumor formation ability of nasopharyngeal carcinoma cells.
Carcinogenesis. 30:2085–2094. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shi X, Franko B, Frantz C, Amin HM and Lai
R: JSI-124 (cucur-bitacin I) inhibits Janus kinase-3/signal
transducer and activator of transcription-3 signalling,
downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and
induces apoptosis in ALK-positive anaplastic large cell lymphoma
cells. Br J Haematol. 135:26–32. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jing N and Tweardy DJ: Targeting Stat3 in
cancer therapy. Anticancer Drugs. 16:601–607. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee DH, Thoennissen NH, Goff C, Iwanski
GB, Forscher C, Doan NB, Said JW and Koeffler HP: Synergistic
effect of low-dose cucurbitacin B and low-dose methotrexate for
treatment of human osteosarcoma. Cancer Lett. 306:161–170. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bromberg JF, Wrzeszczynska MH, Devgan G,
Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: Stat3 as an
oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu H and Jove R: The STATs of cancer - new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Darnell JE: Validating Stat3 in cancer
therapy. Nat Med. 11:595–596. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mora LB, Buettner R, Seigne J, Diaz J,
Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, et
al: Constitutive activation of Stat3 in human prostate tumors and
cell lines: Direct inhibition of Stat3 signaling induces apoptosis
of prostate cancer cells. Cancer Res. 62:6659–6666. 2002.PubMed/NCBI
|
|
35
|
Dolled-Filhart M, Camp RL, Kowalski DP,
Smith BL and Rimm DL: Tissue microarray analysis of signal
transducers and activators of transcription 3 (Stat3) and
phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear
localization is associated with a better prognosis. Clin Cancer
Res. 9:594–600. 2003.PubMed/NCBI
|
|
36
|
Leeman RJ, Lui VW and Grandis JR: STAT3 as
a therapeutic target in head and neck cancer. Expert Opin Biol
Ther. 6:231–241. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Song L, Turkson J, Karras JG, Jove R and
Haura EB: Activation of Stat3 by receptor tyrosine kinases and
cytokines regulates survival in human non-small cell carcinoma
cells. Oncogene. 22:4150–4165. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ryu K, Choy E, Yang C, Susa M, Hornicek
FJ, Mankin H and Duan Z: Activation of signal transducer and
activator of transcription 3 (Stat3) pathway in osteosarcoma cells
and overexpression of phosphorylated-Stat3 correlates with poor
prognosis. J Orthop Res. 28:971–978. 2010.PubMed/NCBI
|
|
39
|
Niu G, Heller R, Catlett-Falcone R,
Coppola D, Jaroszeski M, Dalton W, Jove R and Yu H: Gene therapy
with dominant-negative Stat3 suppresses growth of the murine
melanoma B16 tumor in vivo. Cancer Res. 59:5059–5063.
1999.PubMed/NCBI
|
|
40
|
Duncan MD and Duncan KL: Cucurbitacin E
targets proliferating endothelia. J Surg Res. 69:55–60. 1997.
View Article : Google Scholar : PubMed/NCBI
|
